Ongeno key facts
as of Oct 2026- Operator of a medical technology intended to treat several autoimmune diseases.
- Ongeno is valued at approximately $72.6M as of Oct 2026 (last reported valuation).
- It has raised $3.6M; the latest was Later Stage VC ($3.6M) in Jan 2025.
- Notable investors include JRH.
- Status: Privately Held (backing).
Ongeno's last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·Watch Ongeno: the Monday email on marks, rounds and moves
Ongeno funding rounds
No funding rounds for Ongeno are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Ongeno
1Ongeno valuation
Ongeno's last reported valuation was $72.6 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
Ongeno investors
1 investor is on record for Ongeno, including JRH. By type, the record holds 1 venture capital firm.
About Ongeno
Operator of a medical technology intended to treat several autoimmune diseases. The company focuses on the use of stem cells in regenerative medicine and uses autological transfer of bone marrow stem cells, enabling the healthcare industry to treat multiple sclerosis.
- Sector
- Healthcare
- HQ
- Krakow, Poland
- Founded
- 2017
- Employees
- 2
- Website
- ongeno.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.